Last checked at 10 Jan 2023 12:24
10 January 2023
CVS Group Plc
("CVS" or the "Company")
Exercise of SAYE Options, PDMR Dealing
and Total Voting Rights
CVS, one of the UK's leading providers of integrated veterinary services, announces that on 10 January 2023, options over a total of 106,955 ordinary shares of 0.2 pence each (the "Ordinary Shares") were exercised under the CVS Group 2019 SAYE Plan (2019/2023), at an exercise price of £8.63. Additionally, deferred options over a total of 1,474 Ordinary Shares were exercised under the CVS Group 2018 SAYE Plan (2018/2022) taking the total options exercised on 10 January 2023 to 108,429.
The sum of 108,429 new Ordinary Shares were issued to satisfy the balance of Ordinary Shares arising from the SAYE Exercise. Admission of the 108,429 new Ordinary Shares has been satisfied by the Company's block listing admitted to the London Stock Exchange on 30 December 2021.
Robin Alfonso, Chief Financial Officer exercised options over 709 Ordinary Shares in the Company. The balance of the options were exercised by certain other employees and former employees of the Company.
Following his option exercise, Robin Alfonso holds a beneficial interest in 12,151 Ordinary Shares in the Company, representing approximately 0.017 per cent of the total voting rights of the Company, calculated on the same basis.
Following the issue of the new Ordinary Shares, the Company has a total issued share capital of 71,380,400 Ordinary Shares each carrying one voting right. The Company holds no Ordinary Shares in treasury. Therefore, following the issue of the new Ordinary Shares, the total number of voting rights in the Company will be 71,380,400. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Contacts:
CVS Group plc via Camarco
Richard Fairman, CEO
Jenny Farrer, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900
Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
Toby Strong +44 (0)7789 151 644
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Robin Alfonso |
2 | Reason for the notification | |
a) | Position/status | Chief Financial Officer |
b) | Initial notification /Amendment | Initial Notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | CVS Group plc |
b) | LEI | 213800J41XDQ2NX48O05 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 0.2 pence each
GB00B2863827 | ||||||||||
b) | Nature of the transaction | Exercise of options under the 2019 SAYE Plan (1 January 2023 maturity)
| ||||||||||
c) | Price(s) and volume(s) |
| ||||||||||
d) | Aggregated information
- Aggregated volume
- Price |
N/A - single transaction | ||||||||||
e) | Date of the transaction | 10 January 2023 | ||||||||||
f) | Place of the transaction | London Stock Exchange - AIM |